Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

H Yamaguchi, JM Hsu, WH Yang… - Nature Reviews Clinical …, 2022 - nature.com
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
被引用次数：213 相关文章

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.

H Yamaguchi, JM Hsu, WH Yang… - Nature reviews. Clinical …, 2022 - europepmc.org
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

[引用][C] Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

H Yamaguchi, JM Hsu, WH Yang… - Nature Reviews Clinical …, 2022 - cir.nii.ac.jp
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel
small-molecule therapeutics | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

H Yamaguchi, JM Hsu, WH Yang… - Nature reviews …, 2022 - pubmed.ncbi.nlm.nih.gov
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …